2026-01-16
Segulah Medical Acceleration is pleased to highlight an important milestone for our portfolio company SAGA Diagnostics, which has expanded its ultra-sensitive MRD platform Pathlight™ into a second indication: colorectal cancer (CRC).
Pathlight MRD has been built from the ground up on structural variants (SVs) – some of the most stable and informative markers of tumor biology. By leveraging SVs rather than relying solely on point mutations, Pathlight is designed to deliver earlier detection of molecular recurrence, clearer readouts, and more informed treatment decisions for patients and clinicians.
Following strong performance and growing clinical adoption in breast cancer, Pathlight MRD is now being introduced for colorectal cancer, bringing the same SV-based, tumor-informed approach to a new patient population. This expansion underscores both the versatility of SAGA’s technology and the broader potential for MRD-guided precision oncology across solid tumors.
We are proud to support SAGA Diagnostics as they bring this next-generation MRD solution to the CRC community and continue to partner with clinicians at the forefront of cancer care.
Read the full press release from SAGA Diagnostics here